Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 18;65(4):e00065-21.
doi: 10.1128/AAC.00065-21. Print 2021 Mar 18.

Considering Personalized Interferon Beta Therapy for COVID-19

Karim Dorgham  1 , Avidan U Neumann  2   3 , Maxens Decavele  4   5 , Charles-Edouard Luyt  6   7 , Hans Yssel  8 , Guy Gorochov  8   9
Affiliations
Comment

Considering Personalized Interferon Beta Therapy for COVID-19

Karim Dorgham et al. Antimicrob Agents Chemother. .
No abstract available

Keywords: COVID-19; biotherapy; interferon beta.

PubMed Disclaimer

Figures

FIG 1
FIG 1
IFN-β levels among healthy controls and COVID-19 patients. Patients (n = 112) presenting with a positive SARS-CoV-2 real-time reverse transcriptase-PCR result from their nasopharyngeal swab and pulmonary involvement were included at hospital admission. Mortality was assessed at day 30 after admission. Sampling times from onset of symptoms varied between 0 and 25 days (median, 9 days). Healthy SARS-CoV-2-negative individuals (n = 10) were included as controls. For all individuals, sera were stored less than 4 h after collection at −80°C. Serum IFN-β levels were measured by a highly sensitive enzyme-linked immunosorbent assay (ELISA; VeriKine-HS human IFN-β ELISA kit; PBL Assay Science, Piscataway, NJ, USA). Symbols represent individual patients. The dashed line represents the limit of detection (0.59 pg/ml). The dotted line represents the 90th percentile of IFN-β levels (3.4 pg/ml). A P value for COVID-19 mortality was calculated for patients with detectable IFN-β levels. The statistical significance of differences between groups was assessed using the nonparametric Mann-Whitney test and the Fisher-exact test. The study was performed at the AP-HP Pitié-Salpêtrière Hospital in Paris, France, and approved by the local ethical committee (approvals CER-SU-2020-21 and -31). BLD, below the limit of detection.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS. 2020. A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19. Antimicrob Agents Chemother 64:e01061-20. doi:10.1128/AAC.01061-20. - DOI - PMC - PubMed
    1. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA, Inhaled Interferon Beta COVID-19 Study Group . 12 November 2020. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med doi:10.1016/S2213-2600(20)30511-7. - DOI - PMC - PubMed
    1. Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY. 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395:1695–1704. doi:10.1016/S0140-6736(20)31042-4. - DOI - PMC - PubMed
    1. Arabi YM, Asiri AY, Assiri AM, Balkhy HH, Al Bshabshe A, Al Jeraisy M, Mandourah Y, Azzam MHA, Bin Eshaq AM, Al Johani S, Al Harbi S, Jokhdar HAA, Deeb AM, Memish ZA, Jose J, Ghazal S, Al Faraj S, Al Mekhlafi GA, Sherbeeni NM, Elzein FE, Al-Hameed F, Al Saedi A, Alharbi NK, Fowler RA, Hayden FG, Al-Dawood A, Abdelzaher M, Bajhmom W, AlMutairi BM, Hussein MA, Alothman A, Saudi Critical Care Trials Group . 2020. Interferon beta-1b and lopinavir-ritonavir for Middle East respiratory syndrome. N Engl J Med 383:1645–1656. doi:10.1056/NEJMoa2015294. - DOI - PubMed
    1. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, Pere H, Charbit B, Bondet V, Chenevier-Gobeaux C, Breillat P, Carlier N, Gauzit R, Morbieu C, Pene F, Marin N, Roche N, Szwebel TA, Merkling SH, Treluyer JM, Veyer D, Mouthon L, Blanc C, Tharaux PL, Rozenberg F, Fischer A, Duffy D, Rieux-Laucat F, Kerneis S, Terrier B. 2020. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369:718–724. doi:10.1126/science.abc6027. - DOI - PMC - PubMed

LinkOut - more resources